Royce & Associates LP Grows Stock Holdings in AngioDynamics, Inc. $ANGO

Royce & Associates LP boosted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 27.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,267,451 shares of the medical instruments supplier’s stock after acquiring an additional 272,091 shares during the period. Royce & Associates LP’s holdings in AngioDynamics were worth $16,274,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its stake in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in AngioDynamics during the third quarter valued at $25,000. Washington Trust Advisors Inc. purchased a new stake in AngioDynamics during the third quarter valued at $27,000. State of Wyoming purchased a new stake in AngioDynamics during the second quarter valued at $31,000. Finally, Russell Investments Group Ltd. raised its stake in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Trading Down 1.0%

NASDAQ ANGO opened at $11.80 on Wednesday. The company’s 50-day moving average price is $10.87 and its 200-day moving average price is $11.41. The stock has a market cap of $487.58 million, a PE ratio of -15.73 and a beta of 0.37. AngioDynamics, Inc. has a 12 month low of $8.36 and a 12 month high of $13.99.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The firm had revenue of $78.42 million for the quarter, compared to analysts’ expectations of $76.77 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.19 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ANGO. Canaccord Genuity Group reduced their target price on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Zacks Research downgraded shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AngioDynamics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.